Grant Disick, MD
Urology · Boca Raton, FLNPI 1639236797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in FL, where the typical reported total is $3,881.
Across 161 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$601
- Antares Pharma, Inc.$543
- Astellas Pharma US Inc$420
- Medtronic$283
- Sumitomo Pharma America, Inc.$225
- Coloplast$215
- plus $2K from 29 others
Across 97 payments — averaging $8245.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urovant Sciences Inc$495K
- AbbVie$271K
- GSK$34K
What the payments were for
- Food & beverage$3,89796%
- Education$1424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $601 |
| Antares Pharma, Inc. | 22 | $543 |
| Astellas Pharma US Inc | 15 | $420 |
| Medtronic | 7 | $283 |
| Sumitomo Pharma America, Inc. | 11 | $225 |
| Coloplast | 11 | $215 |
| Boston Scientific | 6 | $186 |
| Urogen Pharma, Inc. | 1 | $141 |
| Pfizer | 6 | $132 |
| Baxter Healthcare | 1 | $115 |
| Endo Pharmaceuticals Inc. | 6 | $112 |
| Myovant Sciences Inc. | 5 | $98 |
| Convatec Inc. | 3 | $94 |
| AstraZeneca | 3 | $82 |
| Caldera Medical, Inc | 1 | $81 |
| Johnson & Johnson | 3 | $76 |
| Tolmar Pharmaceuticals, Inc. | 4 | $76 |
| Halozyme Inc | 3 | $68 |
| Dendreon Pharmaceuticals LLC | 2 | $58 |
| Tolmar, Inc. | 2 | $44 |
| Accord Healthcare, Inc. | 2 | $42 |
| Myriad Genetic Laboratories, Inc. | 2 | $41 |
| Novartis | 1 | $35 |
| Laborie Medical Technologies Corp. | 2 | $34 |
| Siemens Medical Solutions USA, Inc. | 1 | $32 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Procept Biorobotics Corporation | 1 | $23 |
| Teleflex LLC | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Urovant Sciences Inc | 1 | $21 |
| ABC Home Medical Supply, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,039 in reported general payments places this provider in the 50th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 32 | $449,157 |
| NubeqaDarolutamide | 15 | $197,926 |
| OrgovyxRelugolix | 53 | $139,204 |
| MyrbetriqMirabegron | 125 | $80,409 |
| Lupron DepotLeuprolide Acetate | 11 | $64,434 |
| XyostedTestosterone Enanthate | 21 | $12,811 |
| Tamsulosin Hcl | 887 | $11,698 |
| GemtesaVibegron | 14 | $11,210 |
| Finasteride | 607 | $6,995 |
| Testosterone Cypionate | 128 | $5,138 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 183 | $3,751 |
| Silodosin | 37 | $3,019 |
| Oxybutynin Chloride ErOxybutynin Chloride | 104 | $2,478 |
| Solifenacin Succinate | 52 | $2,152 |
| Methenamine Hippurate | 37 | $2,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $420 | $529,567157 claims |
| BayerNubeqa | $19 | $197,92615 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $225 | $150,41467 claims |
| AbbVieLupron Depot | $601 | $64,43411 claims |
| Antares Pharma, Inc.Xyosted | $543 | $12,81121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 urology providers in Florida.
Other urology in Boca Raton
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
- Raymond PakJacksonville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.